Melane Sampson, Author at BioTuesdays

Developments

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and...

January 22, 2025

Developments

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx (NASDAQ:MGTX) has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD)...

January 22, 2025

Developments

Revelation launches Phase 1b study of Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) has announced the commencement of its PRIME Phase 1b clinical study evaluating escalating doses of Gemini, its intravenously administrated proprietary formulation of phosphorylated...

January 21, 2025

Developments

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non...

January 21, 2025

Developments

BioNxt moves R&D to Gen-Plus in Munich

BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective...

January 21, 2025

Feature

VICO addressing severe neurological diseases at the source with RNA modulating therapies

Closely held VICO Therapeutics is developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe genetic neurological diseases, including Huntington’s disease (HD) and spinocerebellar...

January 21, 2025

Developments

R&M features Izotropic in US breast cancer analysis and forecast

Izotropic (CSE:IZO; OTCQB:IZOZF; FSE:1R3) announced its inclusion in a Research and Markets (R&M) report analyzing the US breast cancer screening and diagnostic market. According to Izotropic, the R&M analysis...

January 17, 2025

Developments

Avicanna and Vectura forge scientific and medical affairs collaboration

Avicanna (TSX:AVCN; OTCQX:AVCNF; FSE:ONN) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma to establish a joint committee aimed at enhancing the understanding of medical cannabis...

January 16, 2025

Developments

Peer-reviewed journal accepts Spago’s article on trial results for publication

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) announced that its article on the results of the SPANGOPIX-01 clinical trial of pegfosimer manganese (SN132D) for contrast-enhanced MRI of breast cancer has been accepted for...

January 15, 2025

Developments

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Vistagen (NASDAG:VTGN) announced positive results from its exploratory Phase 2a study of PH284, an investigational pherine nasal spray for cancer cachexia— a condition characterized by appetite loss and severe wasting...

January 15, 2025

Author - Melane Sampson

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

FDA grants RPDD to MeiraGTx’s treatment for LCA1

Revelation launches Phase 1b study of Gemini in CKD

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

BioNxt moves R&D to Gen-Plus in Munich

VICO addressing severe neurological diseases at the source with RNA modulating therapies

R&M features Izotropic in US breast cancer analysis and forecast

Avicanna and Vectura forge scientific and medical affairs collaboration

Peer-reviewed journal accepts Spago’s article on trial results for publication

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Subscribe